Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Eur J Nucl Med Mol Imaging

Search In Journal Title:

Abbravation: European Journal of Nuclear Medicine and Molecular Imaging

Search In Journal Abbravation:

Publisher

Springer Berlin Heidelberg

Search In Publisher:

DOI

10.1002/9780470079072.ch5

Search In DOI:

ISSN

1619-7089

Search In ISSN:
Search In Title Of Papers:

Erratum to Impact of PET/CT image reconstruction

Authors: Georg Kuhnert Ronald Boellaard Sergej Sterzer Deniz Kahraman Matthias Scheffler Jürgen Wolf Markus Dietlein Alexander Drzezga Carsten Kobe
Publish Date: 2015/10/19
Volume: 43, Issue: 1, Pages: 204-205
PDF Link

Abstract

Maximal standard uptake value corrected for body weight SUVmax and for lean body mass SULmax as well as the peak SUV and SUL SUVpeak SULpeak were measured in the single hottest lesion in the lung after OSEM and UHDreconstruction for each patient The corresponding mean values are shown in Table 1 OSEM ordered subset expectation maximization UHD ultra high definition

Keywords:

References

.
Search In Abstract Of Papers:
Other Papers In This Journal:
  1. Protocol for measuring myocardial blood flow by PET/CT in cats
  2. Coronary risk factors and myocardial blood flow in patients evaluated for coronary artery disease: a quantitative [ 15 O]H 2 O PET/CT study
  3. Comparison of [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate and [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotide: which peptide is preferable for PRRT?
  4. Decreased cerebral α4β2* nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer’s disease assessed with positron emission tomography
  5. Assessment of the diagnostic accuracy of 18 F-FDG PET/CT in prosthetic infective endocarditis and cardiac implantable electronic device infection: comparison of different interpretation criteria
  6. Left ventricular diastolic dyssynchrony assessed with phase analysis of gated myocardial perfusion SPECT: a comparison with tissue Doppler imaging
  7. Non-invasive estimation of hepatic glucose uptake from [ 18 F]FDG PET images using tissue-derived input functions
  8. Non-invasive estimation of hepatic glucose uptake from [ 18 F]FDG PET images using tissue-derived input functions
  9. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging
  10. Differentiation of hepatocellular adenoma and focal nodular hyperplasia using 18 F-fluorocholine PET/CT
  11. Pharmacokinetics of [ 18 F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer’s disease
  12. Can 68 GA-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer?
  13. Brain reserve capacity in frontotemporal dementia: a voxel-based 18 F-FDG PET study
  14. In-vivo comparison of the acute retention of stem cell derivatives and fibroblasts after intramyocardial transplantation in the mouse model
  15. Characterization of age/sex and the regional distribution of mGluR5 availability in the healthy human brain measured by high-resolution [ 11 C]ABP688 PET
  16. Assessment of infarct size by positron emission tomography and [ 18 F]2-fluoro-2-deoxy- D -glucose: a new absolute threshold technique
  17. 99m TcO(BAT-NI), a novel nitroimidazole tracer: in vivo uptake studies in ischaemic myocardium
  18. How should we analyse FDG PET studies for monitoring tumour response?
  19. Effects of nicorandil on cardiac sympathetic nerve activity after reperfusion therapy in patients with first anterior acute myocardial infarction
  20. Positron emission tomography in the management of lymphomas: a summary
  21. Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study
  22. Molecular imaging of angiogenesis with SPECT
  23. Impact of 131 I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma
  24. SPECT imaging of D 2 dopamine receptors and endogenous dopamine release in mice
  25. Molecular imaging of vascular cell adhesion molecule-1 expression in experimental atherosclerotic plaques with radiolabelled B2702-p
  26. A comparison of 99m Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping
  27. α v β 3 imaging can accurately distinguish between mature teratoma and necrosis in 18 F-FDG-negative residual masses after treatment of non-seminomatous testicular cancer: a preclinical study
  28. Comparison of the pharmacokinetics of 68 Ga-DOTATOC and [ 18 F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90 Y-DOTATOC therapy
  29. Integrated SPECT/CT for assessment of haemodynamically significant coronary artery lesions in patients with acute coronary syndrome
  30. Losartan renography for the detection of renal artery stenosis: comparison with captopril renography and evaluation of dose and timing
  31. Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy
  32. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut
  33. Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice
  34. Functional sex differences in human primary auditory cortex
  35. Rapid normalization of osseous FDG uptake following traumatic or surgical fractures
  36. Metabotropic glutamate receptor 5 – a promising target in drug development and neuroimaging
  37. Repeatability of hypoxia PET imaging using [ 18 F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial
  38. Assessment of inflammation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia
  39. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer
  40. Drug enhancement of myocardial tracer uptake during myocardial perfusion imaging
  41. Concomitant radio- and fluorescence-guided sentinel lymph node biopsy in squamous cell carcinoma of the oral cavity using ICG- 99m Tc-nanocolloid
  42. Occult lung infarction may induce false interpretation of 18 F-FDG PET in primary staging of pulmonary malignancies
  43. Aortic inflammation, as assessed by hybrid FDG-PET/CT imaging, is associated with enhanced aortic stiffness in addition to concurrent calcification
  44. Preoperative mapping of cortical language areas in adult brain tumour patients using PET and individual non-normalised SPM analyses
  45. Biodistribution and radiation dosimetry of 68 Ga-PSMA HBED CC—a PSMA specific probe for PET imaging of prostate cancer
  46. From the atomon of Democritus to the therapeutic nuclear medicine of today
  47. Post-traumatic biliobronchial fistula demonstrated on hepatobiliary scintigraphy with SPECT/CT
  48. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer
  49. Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[ 18 F]-ADAM in rats and monkeys
  50. Development of 68 Ga-labelled DTPA galactosyl human serum albumin for liver function imaging
  51. Monitoring metastatic lesions in TENIS, initiating multi-targeted tyrosine kinase inhibitors and follow-up: should the newer FDG PET-CT quantitative indices be the defining objective parameter in clinical trials?
  52. Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer
  53. Validation of pixel-wise parametric mapping of myocardial blood flow with 13 NH 3 PET in patients with hypertrophic cardiomyopathy
  54. Rapid optical imaging of human breast tumour xenografts using anti-HER2 VHHs site-directly conjugated to IRDye 800CW for image-guided surgery
  55. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax
  56. Texture analysis of 18 F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy
  57. Texture analysis of 18 F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy
  58. PET imaging of HER1-expressing xenografts in mice with 86 Y-CHX-A″-DTPA-cetuximab
  59. Sensitivity of PET/MRI to detect recurrence of prostate cancer
  60. Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results
  61. Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer
  62. Metabolic-structural concordance in paraneoplastic limbic encephalitis
  63. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer’s disease
  64. Abnormal response to inotropic stimulation in young asymptomatic type I diabetic patients demonstrated by serial gated myocardial perfusion SPECT imaging
  65. The “reset button” revisited: why high activity 131 I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients
  66. Left ventricular dyssynchrony assessed by gated SPECT phase analysis is an independent predictor of death in patients with advanced coronary artery disease and reduced left ventricular function not undergoing cardiac resynchronization therapy
  67. FDG PET/CT methodology for evaluation of treatment response in lymphoma: from “graded visual analysis” and “semiquantitative SUVmax” to global disease burden assessment
  68. Procedure guidelines for PET/CT tumour imaging with 68 Ga-DOTA-conjugated peptides: 68 Ga-DOTA-TOC, 68 Ga-DOTA-NOC, 68 Ga-DOTA-TATE
  69. EANM 2010—Welcome to Vienna!
  70. 18 F-FDG PET/CT imaging versus dynamic contrast-enhanced CT for staging and prognosis of inflammatory breast cancer
  71. In vitro detection of mdr 1 mRNA in murine leukemia cells with 111 In-labeled oligonucleotide
  72. Therapeutic nuclear medicine expands to breast cancer
  73. Introduction to EANM guideline for the preparation of an Investigational Medicinal Product Dossier (IMPD)
  74. Radioiodinated SB 207710 as a radioligand in vivo: imaging of brain 5-HT 4 receptors with SPET
  75. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls
  76. Are Health Technology Assessments a reliable tool in the analysis of the clinical value of PET in oncology? Who audits the auditors?
  77. Defining optimal tracer activities in pediatric oncologic whole-body 18 F-FDG-PET/MRI
  78. The impact of reconstruction method on the quantification of DaTSCAN images
  79. Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma
  80. Role of pre-operative imaging using 99m Tc-MIBI and neck ultrasound in patients with secondary hyperparathyroidism who are candidates for subtotal parathyroidectomy
  81. Intracoronary brachytherapy for in-stent restenosis: will it remain a viable therapy?
  82. Radiation exposure to surgical staff during F-18-FDG-guided cancer surgery
  83. The role of 131 I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
  84. Breast lymphatic drainage via the pulmonary lymphatic system
  85. Respiratory motion artefact in the liver dome on FDG PET/CT: comparison of attenuation correction with CT and a caesium external source
  86. Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype
  87. Feasibility of sodium/iodide symporter gene as a new imaging reporter gene: comparison with HSV1-tk
  88. Value of 11 C-choline PET and PET/CT in patients with suspected prostate cancer
Search Result: